Nina Worel ¹, Behrouz Mansouri Taleghani ², Erwin Strasser ³ Transfus Med Hemother 2019 Dec;46(6):394-406. doi: 10.1159/000503937. Epub 2019 Nov 6.

The section “Preparative and Therapeutic Hemapheresis” of the German Society for Transfusion Medicine and Immunohematology (DGTI) has reviewed the actual literature and updated techniques and indications for evidence-based use of therapeutic apheresis in human disease. The recommendations are mostly in line with the “Guidelines on the Use of Therapeutic Apheresis in Clinical Practice” published by the Writing Committee of the American Society for Apheresis (ASFA) and have been conducted by experts from the DACH (Germany, Austria, Switzerland) region.

https://pubmed.ncbi.nlm.nih.gov/31933569/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944925/

M Hachiya, T Sakurai, Y Nagata, A Hidaka, Y Akita, H Miyashita, Y Maruyama, R Miyazaki, M Noguchi, R Sawada, J Mitobe, M Mitsunaga, T Yamasaki, T Kato, M Saruta, Journal of Crohn’s and Colitis, Volume 12, Issue supplement_1, February 2018,

Approximately 30% of all cases and 50% of severe cases that had received biologics were not able to avoid surgery. In severe cases, it is important to evaluate early treatment efficacy and prognostic factors because the median time of administration of biologics was only 9 weeks. However, no independent prognostic factor was found in this study.

https://academic.oup.com/ecco-jcc/article/12/supplement_1/S173/4808214

Yong Eun Park ¹, Jae Hee Cheon ^1 2 , Korean J Intern Med. 2018 Jan;33(1):1-19.

Recently, there has been a line of evidence suggesting that biologics such as infliximab and adalimumab are effective in treating intestinal BD. Moreover, new biologics targeting proteins other than tumor necrosis factor α are emerging and are under active investigation. Therefore, in this paper, we review the current therapeutic strategies and new clinical data for the treatment of intestinal BD.

https://pubmed.ncbi.nlm.nih.gov/29207867/

Yuko Higashi ¹, Mitsuyoshi Shimokawa, Kazuhiro Kawai, Takuro Kanekura, J Dermatol. 2013 Dec;40(12):1042-4.

We present a 39-year-old pregnant woman with Behçet’s disease who was treated successfully with granulocyte and monocyte adsorption apheresis (GMA). There were no complications or adverse effects during her pregnancy and delivery. The neonate manifested no abnormalities.

https://pubmed.ncbi.nlm.nih.gov/24303809/

J. Muñoz, M. Clavo, O. Garcia, D. Reina, A. Vidaller, R. Lafuente & L. I. Massuet

ISBT Science Series (2007) 2, 96–101

There is a strong basis to support the modulators properties of innate immunity of GCAP, although there is a lack of data that explains deeply the interactions between the mechanisms involved. GMA may represent a new therapy that offers not a single pathway effect but a global modulation of the most important pathways involved in innate immune response. Future investigations should elucidate the intimate mechanism of action.

https://www.researchgate.net/publication/239319651_Adsorptive_monocyte_and_granulocyte_apheresis_in_the_chronic_inflammatory_illness_ulcerous_colitis_Crohn’s_disease_rheumatoid_arthritis_and_Behcet_syndrome

Kenichi Namba ¹, Koh-Hei Sonoda, Hirokuni Kitamei, Kenji Shiratori, Akiko Ariyama, Kazuya Iwabuchi, Kazunori Onoé, Abby R Saniabadi, Shoichi Inaba, Tatsuro Ishibashi, Shigeaki Ohno, J Clin Apher. 2006 Jul;21(2):121-8

We conclude that granulocytapheresis might be effective and safe for patients with refractory ocular BD. Further studies are necessary to fully evaluate the clinical efficacy of granulocytapheresis for BD.

https://pubmed.ncbi.nlm.nih.gov/16395727/

Koh-Hei Sonoda ¹, Shoich Inaba, Akiko Ariyama, Yoh-Ich Kawano, Abby Saniabadi, Tatsuro Ishibashi, Arch Ophthalmol. 2005 Feb;123(2):267-9.

https://pubmed.ncbi.nlm.nih.gov/15710830/